EGFR and breast cancer: For instance, by comparing gene expression profiles to immunohistochemical results obtained using technically well-established antibodies, Nielsen et al. [5] defined basal-like breast cancer as any staining with CK5/6 or epidermal growth factor receptor (EGFR) antibodies in the context of HER2 and ER negativity (Figure 1).